Gallery
- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Gaurav Bidhuri, 2017 World Boxing Championship bronze medallist, joined hands with the Del
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
- FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant
- Ecuador ready to make history against Uruguay: Beccacece
Oxford Covid vaccine shows strong immune response in older adults Last Updated : 19 Nov 2020 06:12:44 PM IST Oxford vaccine Covid-19 vaccine being developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University produced a strong immune response in older adults, raising hopes that it can protect the age groups most at risk from the virus.
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus."We were pleased to see that our vaccine was not only well-tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers," Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, was quoted as saying to the BBC."The next step will be to see if this translates into protection from the disease itself," Ramasamy added.According to the researchers, two weeks after the second dose, more than 99 per cent of participants had neutralising antibody responses. These included people of all ages.The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age."The robust antibody and T-cell responses were seen in older people in our study are encouraging. The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults," Ramasamy said."We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure," she added.According to the study, older adults were also less likely to experience side-effects, which were usually mild. And there were no serious safety issues relating to the vaccine, called ChAdOx1 nCov-2019.Three vaccines - Pfizer-BioNTech, Sputnik and Moderna -- have already reported good preliminary data from phase three trials, with one suggesting 94 per cent of over-65s could be protected from Covid-19.IANS London For Latest Updates Please-
Join us on
Follow us on
172.31.16.186